Investment Rating - The report assigns a "Buy" rating for the company, indicating an expected relative performance increase of over 20% in the next six months compared to the relevant market index [14]. Core Insights - The company has achieved performance in line with expectations, driven by dual engines of growth, with significant revenue contributions from its key products [1][7]. - The revenue forecast for the company shows a substantial increase, with projected revenues of 5.7 billion CNY in 2025, growing to 36.5 billion CNY by 2028, reflecting a compound annual growth rate (CAGR) of over 200% from 2025 to 2028 [2][10]. - The company has a strong pipeline, with key products like Olverembatin and Lisatoclax showing promising growth trajectories and clinical advancements [7][9]. Financial Summary - Revenue projections for the company are as follows: - 2025: 5.7 billion CNY - 2026: 7.9 billion CNY - 2027: 12.1 billion CNY - 2028: 36.5 billion CNY - The expected growth rates for revenue are -41.46% in 2025, followed by 38.40% in 2026, 52.50% in 2027, and a remarkable 201.15% in 2028 [2][10]. - The net profit attributable to the parent company is projected to improve from -1,242.77 million CNY in 2025 to a profit of 178.75 million CNY in 2028, indicating a significant turnaround [2][10]. - Earnings per share (EPS) are expected to transition from -3.33 CNY in 2025 to 0.48 CNY in 2028, reflecting the company's recovery and growth [2][10]. Product Pipeline and Clinical Development - Lisatoclax (APG-2575) has received conditional approval for the treatment of CLL/SLL in China and is undergoing multiple Phase III clinical trials, indicating strong regulatory progress and market potential [7]. - Olverembatin has been included in the national medical insurance catalog, enhancing patient accessibility and affordability, which is expected to drive sales growth [7]. - The company is also advancing its PROTAC platform with APG-3288, which has received IND approval from both the FDA and CDE, showcasing its innovative capabilities [7].

Core Insights - The report from CITIC Securities indicates that Ascentage Pharma (06855) is expected to meet its performance targets for 2025, driven by the commercialization of its products and the potential of its international pipeline [1][3]. Financial Performance - In 2025, the company's product sales and commercialization rights revenue is projected to be 574 million RMB, representing a 90% year-on-year increase [1][3]. - The core product, Olverembatinib, is expected to generate sales of 435 million RMB, an 81% increase year-on-year, with all approved indications included in China's National Medical Insurance Drug List, significantly enhancing accessibility [1][3]. - The second product, Lisatuzumab, achieved sales of 70.58 million RMB within five months of its launch [1][3]. Expenditure Overview - Sales and distribution expenses for 2025 are projected to be 354 million RMB, an increase of 80.4% year-on-year, primarily due to increased commercialization activities [2][4]. - Research and development expenses are expected to reach 1.137 billion RMB, a 20.1% increase year-on-year, mainly due to rising clinical trial costs [2][4]. - Administrative expenses are forecasted to be 246 million RMB, reflecting a 31.6% year-on-year increase [2][4]. Cash Position - As of December 31, 2025, the company is expected to have a cash and bank deposit balance of 2.47 billion RMB, indicating a strong cash position [2][4]. Future Outlook - The focus for future growth is on the clinical progress of core products, with ongoing global Phase III clinical trials for Olverembatinib (including POLARIS-1, POLARIS-2, POLARIS-3) and Lisatuzumab (including GLORA-4, GLORA-3, GLORA, GLORA-2) [2][4]. - Additionally, early Phase I studies for APG-3288 (BTK PROTAC) are expected to commence [2][4]. Revenue Forecast - The report forecasts product revenues of 870 million RMB, 1.273 billion RMB, and 1.797 billion RMB for 2026 to 2028, representing year-on-year growth rates of 52%, 46%, and 41% respectively [2][4].

Group 1 - The Hong Kong pharmaceutical market saw a significant rebound, with the Hong Kong Stock Connect Innovation Drug ETF (159570) rising nearly 3% and achieving a trading volume exceeding 900 million yuan, reflecting strong capital inflow [1] - The ETF's latest scale has surpassed 21.4 billion yuan, leading its peers in the same category [1] - The "20CM Innovation Drug New Species" ETF from Huatai-PineBridge (589120) surged by 4%, with strong capital inflow for two consecutive days [1] Group 2 - Rongchang Biopharmaceutical announced the approval of its antibody-drug conjugate (ADC) Vidi Xituzumab (brand name: Aidiqi®) for a new indication, making it the first domestic ADC therapy approved for treating adult breast cancer patients with low HER2 expression and liver metastasis [3] - Gilead Sciences agreed to acquire Ouro Medicines, which holds approximately 15% equity in Ouro, marking a strategic move in the biopharmaceutical sector [3] Group 3 - WuXi AppTec reported a record high in 2025, achieving revenue of 45.456 billion yuan, a year-on-year increase of 15.8%, and a net profit of 19.195 billion yuan, up 105.2% year-on-year [4] Group 4 - The Hong Kong Stock Connect Innovation Drug ETF (159570) saw most of its underlying index stocks perform positively, with notable gains from companies like Connaissance-B, which rose over 4%, and others like Innovent Biologics and Rongchang Biopharmaceutical, which increased by over 2% [5] Group 5 - The AACR 2026 conference will take place in San Diego, featuring numerous innovative pharmaceutical companies discussing breakthroughs from basic research to clinical translation [6] - Key presentations will include Merck's disclosure of clinical data for MK-2010 and updates from various companies on their clinical trials and research advancements [6][7][8][9] Group 6 - The innovation drug sector is experiencing a surge in funding, with approximately 700 billion yuan raised for research and development from January 1, 2024, to March 21, 2026, across Hong Kong and A-share markets [10] - The BD income and post-listing fundraising are providing substantial financial support for innovative drug companies [10][15] Group 7 - Despite short-term volatility in the innovation drug sector, the long-term growth potential remains intact, with a focus on overseas clinical deployment and product progress becoming critical for future success [16][17] - Leading innovative drug companies are entering a positive cycle of product commercialization, which is expected to exceed market expectations [18]

Investment Rating - The industry investment rating is "stronger than the market" (预计6个月内，行业指数表现强于市场表现5%以上) [34] Core Insights - The domestic pharmaceutical industry is showcasing innovative pipelines at the 2026 AACR conference, indicating a strong competitive edge globally [5] - Investment strategies suggest focusing on innovative treatment areas such as metabolic diseases, chronic diseases, and central nervous system disorders, as well as potential technology platforms like small nucleic acid drugs and CAR-T therapies [6] - The report highlights a slight increase in pharmaceutical financing and a recovery in BD transactions and H-share IPOs, which are revitalizing innovation enthusiasm [6] Summary by Sections Industry Overview - The 2026 AACR conference will take place in San Diego, featuring numerous innovative pharmaceutical companies discussing breakthroughs from basic research to clinical translation [5] - Key presentations include Merck's disclosure of clinical data for MK-2010, Revolution's updates on Pan-Ras assets, and various other companies showcasing their clinical and preclinical data [5] Investment Strategy - The report recommends focusing on companies with strong potential in innovative drug development, including Baiyi Shenzhou, He Yu-B, and others [6] - It emphasizes the growth of external CXO demand and suggests monitoring companies involved in emerging fields like peptides and small nucleic acids [6] Market Performance - The pharmaceutical sector experienced a decline of 2.77% last week, while the Shanghai and Shenzhen 300 index fell by 2.19%, ranking the pharmaceutical industry 8th among 28 sectors [10][19] - The valuation of the pharmaceutical sector is reported at 28.87 times (TTM), with a premium of 6.85% over the overall A-shares [25]

Core Viewpoint - The company is expected to achieve a product revenue of approximately 11.9 billion yuan in 2025, maintaining a strong year-on-year growth rate of about 45% [1] - In Q4, the company achieved a product revenue of around 3.3 billion yuan, with a year-on-year increase of over 60%, validating its strong product competitiveness and commercialization system [1] - The growth is driven by the sustained performance of existing products and rapid market entry of new products, with significant contributions from non-oncology areas [1] Event Summary - On February 4, the company announced its product revenue for 2025, projecting around 11.9 billion yuan for the year and approximately 3.3 billion yuan for Q4 [1] - The Q4 revenue was influenced by the inclusion of six new drugs in the national medical insurance catalog, which led to a one-time inventory adjustment [1] Business Performance - The company has expanded its oncology pipeline to 13 products, demonstrating increasing synergy effects [2] - The successful expansion into chronic disease areas has resulted in outstanding achievements, showcasing strong growth potential across its product line [2] - Key growth drivers include products like Sintilimab, Orelabrutinib, and Lembozole, along with rapid market entry of new products such as Masitinib and Tolebrutinib [1][2] Future Outlook - The company is expected to continue leveraging its core advantages and strategic foresight to drive development across multiple disease areas, aiming to become a leading global biopharmaceutical company [2] - The company has 17 commercialized drugs, with one product under NMPA review and four new drug candidates in Phase III or critical clinical studies, alongside 15 other candidates in clinical research [2] Financial Projections - The company is projected to achieve revenues of 11.968 billion yuan, 22.804 billion yuan, and 26.572 billion yuan for the years 2025, 2026, and 2027, respectively, with net profits of 0.886 billion yuan, 6.679 billion yuan, and 8.004 billion yuan [2] - Following a significant global strategic partnership with Takeda, the company retains 40% rights in the U.S. for IBI363, which is expected to enhance its internationalization efforts [2]

Core Viewpoint - The collaboration between Gakos Pharma and AstraZeneca for the Pan-KRAS inhibitor JAB-23E73 marks a significant milestone in the domestic small molecule oncology drug licensing market, with a total transaction value potentially reaching $19.15 billion [1][2]. Group 1: Collaboration Details - Gakos Pharma has entered into a partnership with AstraZeneca, granting the latter exclusive rights to JAB-23E73 outside of China, while both companies will co-develop and commercialize the product in the Chinese market [1]. - The agreement includes an upfront payment of $100 million and potential milestone payments up to $19.15 billion, along with a share of net sales in markets outside China [1][2]. Group 2: Product and Market Context - JAB-23E73 is an innovative Pan-KRAS inhibitor targeting various KRAS mutation subtypes, currently undergoing Phase I clinical trials in China and the U.S. KRAS mutations account for approximately 23% of all cancer patients [1][2]. - The global market for KRAS inhibitors is still in its early stages, with no approved Pan-KRAS inhibitors to date, presenting a significant commercial opportunity for Gakos Pharma [4][6]. Group 3: Company Background and Financials - Gakos Pharma was established in 2015 and focuses on developing breakthrough drugs in the KRAS and SHP2 inhibitor fields [2]. - The company reported revenues of 45.7 million yuan in the first half of the year, primarily from milestone payments, while incurring a loss of 59 million yuan, indicating a narrowing loss compared to the previous year [8][9]. Group 4: Competitive Landscape - AstraZeneca has a strong track record in oncology, with notable products generating significant sales, such as the EGFR inhibitor Osimertinib, which had global sales of approximately $6.5 billion in 2023 [5]. - The collaboration with Gakos Pharma is part of AstraZeneca's strategy to penetrate the KRAS market, which is considered a "blue ocean" opportunity [5].

Core Insights - The company Ayshun Pharmaceutical-B (06855) has received approval from the FDA and EMA to conduct the global Phase III clinical trial (POLARIS-1) for its novel drug Orebatinib (brand name: Nairike®) in combination with chemotherapy for newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) patients [1][2] - The POLARIS-1 study is an international, multicenter, randomized, open-label Phase III trial aimed at evaluating the efficacy and safety of Nairike® combined with chemotherapy in Ph+ ALL patients [1] - Preliminary data from the POLARIS-1 study indicates a molecular minimal residual disease (MRD) negative rate and complete response (CR) rate of approximately 65% in newly diagnosed Ph+ ALL patients treated with Nairike® and low-intensity chemotherapy, showing significant improvement compared to similar products [2] Company Developments - Nairike® is a first-in-class oral third-generation TKI and the first third-generation BCR-ABL inhibitor approved in China, with commercialization in China managed by Ayshun Pharmaceutical and Innovent Biologics [3] - The drug has received multiple indications for treatment in CML resistance areas and is included in the national medical insurance drug list in China [3] - Ayshun Pharmaceutical signed an exclusive option agreement with Takeda regarding Orebatinib, granting Takeda global development and commercialization rights, excluding certain regions in Greater China [3]

Core Insights - The surge in demand for new drug R&D by Chinese companies has led to a near doubling of the market value of biotech stocks listed in Hong Kong this year [1] - Several biotech firms have raised billions of dollars in Hong Kong under special listing rules, indicating strong investor interest [1] - China's biopharmaceutical industry is transitioning from being a low-cost generic drug supplier to a manufacturer of cutting-edge products, aided by advancements in artificial intelligence [1] Industry Developments - China controls approximately 80% of the global supply chain for active pharmaceutical ingredients (APIs) but is now also home to 23% of next-generation therapeutic candidates [3] - The rise of China's biopharmaceutical sector is attributed to comprehensive reforms in drug approval regulations since 2015 and the inclusion of biotechnology in the "Made in China 2025" strategic plan [3] - As of June this year, China ranks second globally in bioscience research, with six of the top 20 global research institutions located in Chinese universities [3] Cost Competitiveness - From 2017 to 2023, the average patient cost for clinical research of innovative drugs in China is only 30% to 50% of that of multinational companies, enhancing the global competitiveness of Chinese innovative drugs [3] - For instance, the drug Orelabrutinib, developed by Ascentage Pharma for chronic myeloid leukemia, is expected to be priced at one-third to one-fourth of the U.S. developed Iclusig [3] Geopolitical Context - The U.S. has recognized the rise of Chinese pharmaceuticals and has attempted to impose a 100% tariff on imported brand-name drugs unless companies establish manufacturing in the U.S. [5] - This creates a paradox for the U.S., as it seeks to reduce reliance on China while also aiming to lower drug prices, which tariffs cannot achieve simultaneously [5] - Despite tariff barriers, the global demand for high-cost performance innovative drugs remains strong, prompting Chinese biotech firms to accelerate their internationalization efforts [5]

Summary of the Conference Call for Ascentage Pharma Industry and Company Overview - The conference call focuses on Ascentage Pharma, a biopharmaceutical company specializing in innovative cancer therapies, particularly in the field of apoptosis and targeted therapies [2][3]. Key Points and Arguments 1. **Orebatein Expansion**: Orebatein, a third-generation TKI, expanded its indications in October 2023 to cover more CML patients, with expectations to be included in the national health insurance by the end of 2024, significantly enhancing market potential. The domestic sales reached 217 million yuan, with a forecasted doubling for the year [2][4]. 2. **BCL-2 Inhibitor Launch**: Ascentage Pharma launched its first domestic BCL-2 inhibitor, targeting relapsed CLL/SLL, which has a superior administration method compared to venetoclax, faster cellular uptake, and higher safety. Multiple phase III registration trials are ongoing, indicating a broad market outlook [2][4]. 3. **Collaboration with Takeda**: The company entered a licensing agreement with Takeda for the drug Nilotinib, with a total transaction value of 1.3 billion USD, including an upfront payment of 100 million USD. The remaining amount consists of milestone payments and sales sharing, with three phase III registration trials currently in progress [2][5]. 4. **Sales and R&D Expenses**: In the first half of 2024, sales expenses were 138 million yuan, with an annual estimate of 250 to 300 million yuan. R&D expenses reached 529 million yuan, with expectations to exceed 1 billion yuan for the year, indicating a continued increase in R&D investment [2][5]. 5. **Clinical Trials**: Orebatein is undergoing three phase III registration trials, while the BCL-2 inhibitor is also in multiple phase III trials covering AML, CLL/SLL, MDS, and multiple myeloma [2][6]. 6. **CML Market Size**: The global TKI market for CML is approximately 6 billion USD, with the domestic market around 4 billion yuan. The rapid growth of third-generation TKIs is noted, with Nilotinib being the only domestic third-generation TKI, providing a competitive edge [2][7][8]. Additional Important Information 1. **Market Competition**: The global CML TKI market is characterized by the expiration of patents for first and second-generation TKIs, with significant market players like Novartis and Takeda. Orebatein is positioned to complete its overseas phase III trials and apply for market approval by 2026 [7][9]. 2. **Advantages of BCL-2 Inhibitor**: Compared to venetoclax, Ascentage's BCL-2 inhibitor offers advantages in administration, faster cellular uptake, and lower side effects due to a shorter half-life. Ongoing trials include combinations with other therapies for various indications [2][11]. 3. **Future Directions**: Ascentage Pharma aims to continue its focus on apoptosis pathways and advance new L-type inhibitors for solid tumors, while also pursuing international expansion and product innovation to meet market expectations [3][12].

Core Viewpoint - The company is experiencing significant growth in sales of Orelabrutinib, with a projected revenue increase of 93% year-on-year to 217 million yuan in the first half of 2025, driven by effective hospital access and chronic disease management strategies [1] Group 1: Orelabrutinib Sales and Market Position - Orelabrutinib's sales are expected to continue growing due to its inclusion in the medical insurance directory, expanding the patient population eligible for reimbursement [1] - The number of hospitals administering Orelabrutinib increased by 47% year-on-year in the first half of 2025, with extended treatment duration for patients [1] - The long-term follow-up data from the 2022 ASH conference indicates a progression-free survival (PFS) rate of 88.6% at 48 months for Orelabrutinib in treating CML-CP, suggesting its potential for long-term management [1] Group 2: APG-2575 Development and Market Potential - APG-2575 is expected to be approved for domestic market launch in mid-2025, further solidifying the company's position in the hematological oncology sector [1] - APG-2575 is positioned as a potential second BCL-2 inhibitor globally, with a unique daily dose escalation design that allows for rapid achievement of therapeutic doses [1] - Early clinical data suggests that APG-2575 combined with azacitidine shows comparable efficacy to venetoclax while significantly improving safety profiles [1] Group 3: Future Pipeline and Clinical Trials - The company has a robust pipeline with multiple promising candidates, including APG-2449, which is undergoing Phase III trials for ALK-positive NSCLC [2] - APG-5918, an EED inhibitor for anemia-related indications, is in Phase I trials, with a unique mechanism that may provide a competitive edge in the market [4] - Upcoming milestones include the completion of several Phase III clinical trials for key products, which could lead to significant market expansions [5] Group 4: Financial Projections - Revenue projections for the company are estimated at 589 million yuan, 1.509 billion yuan, and 1.449 billion yuan for 2025-2027, reflecting a growth trajectory despite a projected decline in 2025 [6] - The company is transitioning from a biotech to a biopharma entity, with a focus on Orelabrutinib and the high-potential APG-2575 as core products [6]